Bridging
Science and Spirit

I founded Beyond Consulting as a bridge between science, creativity, and community. As a clinical neuropharmacologist, researcher, entrepreneur, and community builder, I bring a multidisciplinary approach to my work. I am currently exploring the frontiers of psychedelics, neurology, women's health, plant medicines, writing, public speaking, and policy—an evolving journey that informs and inspires every project I undertake.

We can always chat about music too, as the Co-Creator of Public Secret music label, agency,
and artist collective.

  • As an operations advisor, I excel at optimizing workflows, managing complex projects, and developing strategic plans. My ability to seamlessly blend analytical rigor with operational acumen, and infuse processes with creativity, makes me uniquely equipped to drive innovations and improvements across diverse environments.

    As a neuropharmacologist, I have a deep understanding of medical therapies, plant medicines, pre-clinical and clinical studies, as well as experience as a published researcher and writer.

    A as a "Projector" (Human Design), I naturally perceive more efficient ways of doing things and am driven to guide others towards those solutions. My strong background in science and clinical practice ensures that my approach to problem-solving is both precise and well-informed. At the same time, my lifelong experience as a creative allows me to weave intuition, empathy, and innovation into my work, making my solutions not only effective but deeply human-centered.

  • My goal is to blend clinical excellence, creativity, and strategic mindset to provide comprehensive guidance and expert advice. Through open access education, research, and by supporting initiatives seeking to make a positive impact, I hope to help redefine the landscape of health and wellness.

Research & Interests

  • -Traumatic brain injury

    -Spinal cord injury

    -Headache

    -Chronic pain

    -Women’s health

    -Hormonal and sexual health

    Research partnership with Dr Evan Cole Lewis

  • Altered states and

    -Physical therapy and rehabilitation

    -Athletic performance and help achieve flow state

    -Relationships, connection to self and to others

    -Women’s hormone health

    -Music and dance

    —

    -The history of plant medicines within my own ancestral culture.

    -Stacking functional and medicinal plants

    -Optimizing the therapeutic experience for patients

    -Advocating for the betterment of patient care through educating and public speaking

    -Can altered states and mystical experiences make us better humans?

    -Dreams and the subconscious

CURRICULUM VITAE

  • Post Graduate and Continuing Medical Education
    i. Certificate of Continuing Medical Education, Psychedelic Medicine Association-Managing Medical Risk in Patients Seeking Psilocybin Therapy

    ii. Certificate of Continuing Medical Education, Therapsil-Psilocybin Prescriber

    iii. Certificate of Continuing Medical Education, Numinus-Molecular Foundations: Psilocybin-Molecular Foundations: MDMA-Molecular Foundations: Ketamine

    iv. Certificate of Continuing Medical Education, Therapsil Prescriber for Psilocybin Therapy, Canada

    Masters of Science Clinical Pharmacology, Faculty of Medicine, University of Montreal
    i. Specializations: neurology, neuro/psychopharmacology
    ii. Research Fellowship: Intensive Care and Traumatic Brain Injury

    Bachelors of Science Biopharmaceutical Sciences, Faculty of Pharmacy, University of Montreal

    Minor Neuropsychology and Linguistics, Faculty of Arts and Science, University of Montreal

  • Founding Advisor, Beyond the Bench, 2022-present

    MDMA Therapy Prescriber (independant), Therapsil Canada, 2024-present

    Psilocybin Therapy Prescriber (independant), Therapsil Canada, 2023- present

    Researcher, Neurology Centre of TO, Numinus 2022- present

    Scientific Advisor, Microdosing Collective 501c3, 2022-present

    Therapy Awareness & Market Dev. Advisor, Biosense Webster, Johnson & Johnson - 2018-2022

    Field Trainer & Educator, Biosense Webster, Johnson & Johnson - 2018-2022

    Sr. Clinical Specialist, Biosense Webster, Johnson & Johnson, 2016-2022

    Researcher & Clinical Study Coordinator, Intensive Care & Internal Medicine, Hôpital du Sacré-Coeur de Mtl, 2015-2017

  • Psychedelic Medicine Association, Member
    Society of physicians, therapists, and industry leaders looking to foster the therapeutic use of psychedelics.

    Therapsil, Non-profit, Member
    TheraPsil is a non-profit coalition dedicated to helping Canadians in medical need access legal, psilocybin-assisted psychotherapy and medical psilocybin.

    American Society for Pharmacology and Experimental Therapies, Member
    Society founded by John Jacob Abel of John Hopkins University to promote growth of pharmacological research.

    Microdosing Collective, 501.c3, Scientific Advisor
    Initiative to promote harm reduction and access to indication based psilocybin microdosing.

    Psychedelics & Pain Association, Advisor, Member
    PPA advances science and public awareness towards a future where psychedelic medicines will significantly reduce chronic pain and suffering.

    Kawasaki Disease Foundation, 501c3, Board Member
    Foundation supporting research and awareness for Kawasaki Disease as well as supporting individuals and families affected by KD.

    1. Persons with Spinal Cord Injury report peripherally dominant serotonin-like syndrome after use of serotonergic psychedelics, Karzon, S*†., Rabinovitch, B*†., Zafar, R., Aziz, A., Nielson, J.L‡, Lewis, EC†§ . Neurotrauma Reports. June 2023. NEUR-2023-0022.R1.

    2. Cognitive and motor function effects of antipsychotics in traumatic brain injury: a systematic review of preclinical studies, Gabrielle Cataford, Pharm.D, Laurie-Anne Monton, Pharm.D, Stephanie Karzon, B.Sc., M.Sc., D. Williamson, et al. Neurotrauma Reports. March 2024. NEUR-2023.0108

    3. A systematic review of interventions to facilitate extubation in patients difficult-to-wean due to delirium, agitation, or anxiety and a meta-analysis of the effect of dexmedetomidine, Sébastien Dupuis PharmD, MSc, Dave Brindamour BPharm, MSc, Stephanie Karzon BSc, MSc, Anne Julie Frenette BPharm, MSc, Emmanuel Charbonney MD, PhD, Marc M. Perreault PharmD, MSc, Patrick Bellemare MD, Lisa Burry PharmD & David R. Williamson BPharm, MSc, PhD, 9 Jan 23. PMID: 30674004.